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(EIEC): results of a multicenter cross-
sectional study in the Netherlands during
2016–2017
Maaike J. C. van den Beld1,2* , Esther Warmelink3, Alexander W. Friedrich2, Frans A. G. Reubsaet1,
Maarten Schipper4, Richard F. de Boer5, Daan W. Notermans1, Mariska W. F. Petrignani6,7, Evert van Zanten5,
John W. A. Rossen2, Ingrid H. M. Friesema8, A. M. D. ( Mirjam) Kooistra-Smid2,5 and on behalf of the IBESS working
group
Abstract
Background: Shigella spp. and entero-invasive E. coli (EIEC) use the same invasive mechanism to cause diarrheal
diseases. Public health regulations apply only to Shigella spp. infections, but are hampered by the lack of simple
methods to distinguish them from EIEC. In the last decades, molecular methods for detecting Shigella spp. and EIEC
were implemented in medical microbiological laboratories (MMLs). However, shigellosis cases identified with
molecular techniques alone are not notifiable in most countries. Our study investigates the impact of EIEC versus
Shigella spp. infections and molecular diagnosed shigellosis versus culture confirmed shigellosis for re-examination
of the rationale for the current public health regulations.
Methods: In this multicenter cross-sectional study, fecal samples of patients suspected for gastro-enteritis, referred
to 15 MMLs in the Netherlands, were screened by PCR for Shigella spp. or EIEC. Samples were cultured to
discriminate between the two pathogens. We compared risk factors, symptoms, severity of disease, secondary
infections and socio-economic consequences for (i) culture-confirmed Shigella spp. versus culture-confirmed EIEC
cases (ii) culture positive versus PCR positive only shigellosis cases.
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Results: In 2016–2017, 777 PCR positive fecal samples with patient data were included, 254 of these were culture-
confirmed shigellosis cases and 32 were culture-confirmed EIEC cases. EIEC cases were more likely to report
ingestion of contaminated food and were less likely to be men who have sex with men (MSM). Both pathogens
were shown to cause serious disease although differences in specific symptoms were observed. Culture-negative
but PCR positive cases were more likely report travel or ingestion of contaminated food and were less likely to be
MSM than culture-positive cases. Culture-negative cases were more likely to suffer from multiple symptoms. No
differences in degree of secondary infections were observed between Shigella spp. and EIEC, and culture-negative
and culture-positive cases.
Conclusions: No convincing evidence was found to support the current guidelines that employs different
measures based on species or detection method. Therefore, culture and molecular detection methods for Shigella
spp. and EIEC should be considered equivalent for case definition and public health regulations regarding
shigellosis. Differences were found regarding risks factors, indicating that different prevention strategies may be
required.
Keywords: Shigella, Shigellosis, Entero-invasive Escherichia coli, EIEC, Clinical implications, Public health, Incidence,
Infectious disease control, Guidelines, Case definition,
Background
Shigella spp. are one of the leading causes for diarrheal
mortality and morbidity, predominantly in resource-
restricted areas [1]. In resource-rich areas imported and
domestically acquired shigellosis poses a substantial
burden on public health due to the use of healthcare
facilities, requirement for disease control measures, and
a high number of disability adjusted life years [1–4].
Entero-invasive Escherichia coli (EIEC) is a pathotype of
E. coli that causes diarrhea, using the same invasive mech-
anisms as Shigella spp. [5, 6]. Shigella spp. and EIEC result
from the convergent evolution of ancestral E. coli which
independently acquired the large invasion virulence plas-
mid (pINV) on multiple occasions [7]. Genetically, Shi-
gella spp. and EIEC share virulence genes. Furthermore,
they are related to such an extent that they should be clas-
sified as one species together with other E. coli pathotypes
and commensals, however the current designation of two
genera is maintained [8, 9].
Molecular detection of Shigella spp. and EIEC from fecal
samples based on the presence of virulence genes such as
the ipaH-gene greatly improved diagnostics [10]. How-
ever, because of their shared characteristics, differentiating
EIEC from Shigella spp. in the routine medical microbiol-
ogy laboratory (MML) is difficult. In the last decade, mul-
tiple research groups developed molecular markers or
methods that aimed to distinguish Shigella spp. from EIEC
[8, 11–15]. While most of these methods were able to cor-
rectly identify isolates in the isolate set of their developers,
it was demonstrated that these molecular methods have
difficulties identifying other isolates, particularly EIEC
isolates ( [8, 13, 14] van den Beld et al., submitted). These
complications with molecular assay development are
probably caused by the high heterogeneity of EIEC iso-
lates, leading to the identification of subgroups rather than
the whole pathotype EIEC ( [8, 16], van den Beld et al.,
submitted). Moreover, differentiating cultured isolates
based on physiological and biochemical properties is com-
plicated, as EIEC can display either an E. coli-like profile
or a more inactive Shigella-like profile, and all profiles in-
between [17]. Nevertheless, culturing is performed for sev-
eral reasons. First, culturing for antimicrobial susceptibi-
lity testing is pivotal, as Shigella spp. are on the global
priority list for antibiotic-resistant bacteria [18]. Second,
to distinguish Shigella spp. from EIEC, culture-dependent
identification methods are required, as molecular methods
cannot be used for this purpose [5, 17]. This distinction is
only important because EIEC infections are not notifiable
in most countries while shigellosis is. Furthermore, in the
Netherlands, as in many other countries, confirmed case
definitions for shigellosis in control regulations specifically
require the isolation of Shigella spp. [19–22].
Despite these advantages of culturing, culture
methods for Shigella spp. are known to have limited
sensitivity [23, 24]. Isolation of EIEC from fecal samples
is even more challenging, as selective agar plates are
based on biochemical properties such as fermentation
of lactose and decarboxylation of lysine that EIEC
shares with some other Enterobacteriaceae present in
the gut [25].
The similarity between Shigella spp. and EIEC makes
regulations, which require the notification of Shigella
spp. but not EIEC, difficult to apply in practice by both
laboratories and physicians. Apart from some studies
that describe the infectious potential of EIEC and their
ability to cause food related outbreaks, limited research
has been performed on this subject [26–30]. Therefore,
little is known of the severity and sequela of EIEC with
respect to the incidence and impact on individual
patients or public health.
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Additionally, public health authorities struggle with
the control of shigellosis cases identified with molecu-
lar techniques alone, because the impact of these
cases for patients and public health is also not well
defined [31, 32]. Two studies have looked at differ-
ences in case demographics, risk factors, and disease
outcomes of shigellosis in culture-positive cases ver-
sus culture-negative cases [31, 33]. However, in both
studies the proportion of EIEC infections amongst the
culture-negative cases was unknown, and in one of
the studies the data was biased because laboratory
testing was unevenly distributed between laboratories
that used either culture methods or molecular
methods [31, 33].
To obtain a more complete insight into the implica-
tions of infections with Shigella spp. and EIEC and the
challenges regarding their detection, distinction and
control measures, a multicenter cross-sectional observa-
tional study was performed in the Netherlands ‘the
Invasive Bacteria E. coli-Shigella Study’ (IBESS). We
compared results with regard to incidence, clinical impli-
cations and impact on public health for (i), infections
with EIEC or Shigella spp. and (ii), culture confirmed
shigellosis versus molecular detected shigellosis. With
this study, more evidence is obtained for improvements
of the guidelines for control of shigellosis.
Methods
Study design and inclusion criteria
During 2016 and 2017, 15 medical microbiological la-
boratories (MMLs) and their respective public health
services (PHS) participated in this study. Fecal samples
from patients suspected for gastro-enteritis that were re-
ferred to one of the participating MMLs for regular diag-
nostics, in which Shigella spp. or EIEC was detected with
molecular methods, were included. After inclusion, the
DNA eluate of the fecal sample and, if available, a cul-
tured isolate were sent to the study group. A molecular
algorithm based on the ratio of Ct-values of the ipaH
gene and the Shigella wzx genes was used to serotype
directly from fecal samples [34]. In addition, all obtained
isolates were identified and serotyped with classical
methods as previously described [34] (Fig. 1). Further-
more, clinical and epidemiological data were collected
from all included patients (Fig. 1).
Data collection
Data was collected from patients using two approaches.
For fecal samples of which a Shigella spp. was isolated,
which are notifiable under current regulations, PHS per-
formed source tracing according to the guidelines. Pa-
tients were informed about the study and requested to
give consent for their participation in this study after
Fig. 1 Overview of the design of the IBESS-study. Grey boxes = activities performed by participating laboratories. White boxes = activities
performed by the IBESS-study group
Beld et al. BMC Infectious Diseases         (2019) 19:1037 Page 3 of 12
completion of the regular survey regarding source tra-
cing for shigellosis. After consent, an infectious disease
nurse from the study group contacted them by tele-
phone. They were informed again about the study and,
after their further consent, subjected to a single survey
to collect additional clinical and epidemiological data. In
contrast, for fecal samples of which Shigella spp. or EIEC
was detected with molecular methods only or from
which an EIEC isolate was cultured, an infectious disease
nurse from the study group contacted the physicians of
the patients first to request their permission for contact-
ing the patients. After their consent, the patient was
contacted by the infectious disease nurse for collection
of data as described above.
Incidence
Incidence of Shigella spp. for the years 2016 and 2017
was calculated using the numbers of national shigellosis
notifications as numerator and residents in the
Netherlands on 1 January 2017 as denominator. A multi-
plier of 53 was applied, as for one notified shigellosis
case, 53 cases have been estimated to be to be missed in
the Netherlands due to under-reporting and under-
diagnosing [35].
The proportion of Shigella spp. isolates included in this
study from total notified shigellosis cases was determined,
and was used to calculate the incidence of EIEC by ex-
trapolating the proportion to the EIEC isolates included in
this study to a national level. However, the multiplier that
was modelled to calculate the community incidence for
shigellosis is not suitable to use for EIEC cases. In the al-
gorithm of Haagsma et al., the sensitivity of the laboratory
analysis and the percentage of bloody diarrhea are import-
ant factors used to correct for under-reporting and under-
diagnosing [35]. However, these factors are known to vary
among different enteric pathogens. From an earlier study,
it is known that only 5 out of 16 MMLs performed culture
of EIEC in the Netherlands. This proportion was multi-
plied with the laboratory analysis sensitivity of 0.63 as pro-
posed for shigellosis by Haagsma et al., resulting in a
sensitivity of 0.20 for laboratory analysis of EIEC [35]. This
factor was used in the calculation of a specific multiplier
for the community incidence of EIEC infections, together
with the fraction of patients with EIEC infections that re-
ported bloody diarrhea in the study described here, which
was 0.16. The country specific parameters for the
Netherlands as reported earlier were maintained [35].
Data and analysis
The following patient variables were collected: risk factors
for infection, clinical symptoms, presence and number of re-
lated patients indicative for the degree of secondary infec-
tions, and socio-economic consequences. The patients
themselves provided variables in a telephone interview. In
an effort to assess the degree of secondary infections, they
were specifically asked if they knew of other people who fell
ill before or after their own onset of symptoms to exclude
common sources of infection. All reported underlying dis-
eases and medication use reported by patients were stratified
into categories and considered as factors. Clinical symptoms
were self-reported and not measured or verified by a phys-
ician. To assess the severity of the disease for individual pa-
tients, the total number of reported symptoms by each
individual patient was added up. Additionally, two severity
scales, the de Wit scale and the modified Vesikari-scale
(MVS), were applied in which higher scores indicated more
severe course of disease [36, 37]. Co-infections with other
enteric pathogens were reported by the participating MMLs
if detected by molecular methods, culture or microscopy.
The study group determined identity of the obtained isolates
and bacterial load in fecal samples was estimated by cycle-
threshold (Ct) values of the ipaH gene following from the
molecular algorithm that was used for the direct Shigella
serotyping in fecal samples. Bacterial load and species desig-
nations were only considered in the comparison of culture-
positive to culture-negative shigellosis cases because it is
known that culture rates increase with an increase in bacter-
ial load (decrease in Ct-value) and that S. sonnei is easier to
detect by culture than S. flexneri [23, 38].
As data was actively retrieved, missing values were
scarce, and included as missing in the statistical analysis.
Comparisons were made for patients with Shigella spp.
to patients with EIEC to assess support for the current
guidelines in which culture confirmed infections with
Shigella spp. are notifiable, while infections with EIEC
are not. Additionally, culture-positive cases were com-
pared with culture-negative shigellosis cases, to assess
support for the current case definition of shigellosis, in
which only culture-confirmed cases are notifiable. To
examine if large dissimilarities exist for infections with
different Shigella spp., infections with cultured S. flexneri
and S. sonnei were also compared.
For the comparison of culture-positive with culture-
negative cases, only infections with S. flexneri and S. sonnei
were analyzed. S. boydii and S. dysenteriae were excluded
because of low case numbers (n < 5). Molecular Shigella
serotyping by real-time PCR in culture-negative samples
was based on the ipaH gene, the S. sonnei wzx gene, and
the S. flexneri wzx1–5 or wzx6 gene as described before [34].
As the ipaH gene is present in multiple copies, in contrast
to the wzx genes, their Ct-values should represent these
ratios to confirm the direct identification of S. sonnei and
S. flexneri by molecular methods. Infections were defined
as culture-positive if S. flexneri or S. sonnei was isolated
from the fecal sample.
Differences in risks factors between groups were calcu-
lated with univariate and multivariate analyses using
logistic regression. All variables with p < 0.20 in the
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univariate analysis were included in the multivariate
model, where the least significant variables were one-by-
one eliminated until all remaining variables reached sig-
nificance (p value< 0.05). Analyses were performed using
SAS® software version 9.4 (SAS Institute Inc., Cary, NC,
USA), odds ratios with their 95% confidence intervals
were calculated using the beta and standard error (SE)
values from the logistic regression models.
Differences in symptoms, severity of disease, degree
of secondary infections and socio-economic conse-
quences were calculated using multivariate analyses
with the following confounders: sex, age, MSM con-
tact, co-infections, effect of underlying diseases or
medication use, and Ct values as measure for bacter-
ial load. In the multivariate analyses for the compari-
son of culture-positive infections and culture-negative
infections, the confounder “species” was added, be-
cause S. flexneri showed lower culture rates (38%)
than S. sonnei (63%). These analyses were performed
using R. version 3.4.3 [39]. and significance was
defined as p < 0.05.
Results
In our study, 1199 PCR positive fecal samples were in-
cluded over the course of 2 years (Fig. 2). From the fecal
samples, 414 isolates were cultured and initially identi-
fied as 232 S. sonnei, 100 S. flexneri, 64 EIEC, 10
provisional Shigella, 3 S. boydii, for the remaining 5
isolates a distinction between S. flexneri and EIEC could
not be made. Shigella were called provisional if the sero-
type could not be determined, or if the established sero-
type did not match with the phenotype. In total, 777
(65%) patients provided clinical and epidemiological
data. Samples of these patients were included for the
comparisons described below (Fig. 2). In total, 290 of the
777 patients had a culture-positive infection. The data of
patients from whom a S. sonnei, S. flexneri, S. boydii or
provisional Shigella (n = 255) isolate was obtained were
used in the comparison to patients of whom an EIEC
isolate (n = 33) was cultured (Fig. 2). For comparison of
culture positive cases to culture negative cases, only data
from patients of which S. sonnei or S. flexneri was
cultured (n = 245) were compared to patients of which
Fig. 2 Flowchart of inclusions in the study. Yellow boxes = data used in this study. White boxes = data not used in this study. Red diamonds =
Data of patients from whom these isolates were obtained were used in the comparison of Shigella spp. with EIEC. Blue diamonds = Data of
patients from whom an S. sonnei or S. flexneri isolate was obtained or detected in the fecal samples were used in the comparison of culture-
positive cases with culture-negative cases. *one S. flexneri and one EIEC isolate were excluded from analysis, because they caused
a double-infection
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S. sonnei or S. flexneri was molecularly detected (n= 167)
(Fig. 2). One S. flexneri and one EIEC isolate were excluded
from all analyses because they were cultured from the same
fecal sample.
Assessment of the sensitivity and specificity of the
molecular S. flexneri and S. sonnei serotyping directly
from fecal samples resulted in a sensitivity of 77 and
75%, and a specificity of 98 and 99% respectively.
Incidence
During 2016 and 2017, 873 cases of shigellosis were no-
tified to the health authorities, resulting in an average of
436.5 cases each year. The total number of residents in
the Netherlands on 1 January 2017 was 17,081,507,
resulting in an estimated incidence 135 shigellosis cases
per 100,000 residents per year in the Netherlands during
2016 and 2017. Almost 40 % (39.5%) of all notified shig-
ellosis cases were included in this study. We assumed
the same ratio of EIEC cases having been included in
our study and multiplied their number by 2.53 to esti-
mate the national EIEC incidence rates. As 64 EIEC iso-
lates were cultured, this resulted in 160 EIEC cases in 2
years, i.e., 80 per year. From the estimation for specific
EIEC community incidence followed that a multiplier of
265 should be applied, see Additional file 1 for calcula-
tions. This resulted in 80*265 = 21,200 cases in the
Dutch population, translated to a community incidence
for EIEC of 124 cases per 100,000 residents per year in
the Netherlands during 2016 and 2017.
Risks factors
Our results showed that patients with EIEC infections were
more likely to report ingestion of suspected contaminated
food or water (OR: 3.04 (1.44–6.42)) and less likely to
report MSM contact (OR: 0.21 (0.05–0.98)) as source for
infection compared to patients with Shigella spp. (Table 1).
As expected, Ct-values were approximately three Ct lower
for the culture-positive shigellosis cases (OR: 0.88 (0.84–
0.93)) than for culture-negative cases. Additionally, the pro-
portion of S. flexneri in culture-positive infections was lower
than the proportion in culture-negative infections (OR: 0.32
(0.19–0.54)). Furthermore, assessment of risk factors re-
vealed that culture-positive cases travelled less (OR: 0.40
(0.20–0.78)) and were more likely to report MSM contact
(OR: 3.22 (1.70–6.09)) or an unknown infection source (OR:
1.85 (1.17–2.92)) than culture-negative cases. In addition,
culture-positive cases were less likely to report ingestion of
suspected contaminated food or water as infection source
than culture-negative cases (OR: 0.38 (0.24–0.61)) (Table 1).
Symptoms, severity of disease and socio-economic
consequences
Patients with EIEC infections reported suffering for
longer from diarrhea than patients with Shigella spp.
infection. In addition, the maximum vomiting fre-
quency was higher for patients with EIEC infections
(Table 2). Although patients with EIEC were symp-
tomatic longer, they exhibited fewer symptoms and
scoring lower on the de Wit scale than patients with
Shigella spp. In contrast, no significant difference in
severity was calculated using the MVS scale (Table 2).
For socio-economic consequences, patients with EIEC
infections were more likely to visit a general practi-
tioner (GP) and to have a shorter stay when hospital-
ized than patients with a Shigella spp. infection
(Table 3).
Culture-negative cases were more likely to report nau-
sea, longer duration of diarrhea, vomiting and higher fre-
quencies of vomiting than culture-positive cases (Table 2).
Moreover, the MVS score of culture-negative cases was
significantly higher than that of culture-positive cases,
while the de Wit scores showed no significant difference
(Table 2). In addition, culture-negative cases were more
likely to report longer absence from work compared to
culture-positive cases (Table 3).
Secondary infections
Because there was a lack of specific data about relation-
ships between cases, the presence and number of self-
reported related patients was used as a proxy for the de-
gree of secondary infections. No significant differences
in presence and number of self-reported related patients
were found when comparing EIEC cases with shigellosis
cases or when comparing culture-positive cases to
culture-negative cases (Table 4).
Comparison of infections with cultured S. flexneri and
S. sonnei
First, patients with S. sonnei were more likely to report
(85%) abdominal cramps compared to S. flexneri (75%, p =
0.047). Second, no differences in total number of symptoms
or disease severity were found. Third, patients with S. sonnei
were more likely to self-report the presence of related pa-
tients (45%) than patients with S. flexneri (28%, p= 0.028),
although the self-reported number of related patients did
not differ. Fourth, for the socio-economic consequences,
there were multiple differences: patients with S. flexneri were
more likely to report longer absence from work (median 5
(3–9) days), multiple visits to their GP (average 2.1 visits),
visits to specialists (21%) and hospitalization (17%)
compared to patients with S. sonnei that reported a median
of 4 (2–7), p= 0.001)) days of absence, an average of 1.6 GP
visits (p= 0.049), 10% specialist visits (p= 0.015), and 5%
hospitalization (p < 0.001).
Discussion
This multicenter cross-sectional study was initiated to
obtain more insight into the clinical implications and
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impact on public health of Shigella spp. and EIEC infec-
tions, by assessing differences in incidence, risk factors,
symptoms, severity of disease, degree of secondary infec-
tions and the socio-economic consequences. Addition-
ally, the clinical and public health relevance of detection
of shigellosis with molecular methods only was investi-
gated by comparing culture-positive shigellosis cases to
culture-negative PCR positive shigellosis cases.
The comparison of infections with Shigella spp. and EIEC
showed some differences, for which several hypotheses can
Table 1 Risk factors of infections with EIEC and Shigella, and culture-positive and culture-negative shigellosis
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indicate significant results with p-values <0.05.
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be considered. Patients with EIEC infections were less likely
to report MSM contact than patients with Shigella spp. In-
deed, to our knowledge an EIEC outbreak among MSM has
never been described. The higher infectious dose of EIEC
could explain these lower transmission rates through the sex-
ual route. Although, the claim of the higher infectious dose
for EIEC is based on only one study from the 1970s, in which
only two EIEC isolates were tested for pathogenicity at low
dosages [28]. Despite the fact that patients with EIEC were
symptomatic for longer periods, patients with Shigella spp.
showed more symptoms simultaneously and a higher sever-
ity score on the de Wit scale. However, scores on the MVS
scale were comparable. These discrepancies between the two
disease severity scales were probably caused by the symp-
toms blood in stool and fever. Blood in stool and fever above
37.5 °C is double weighted in the de Wit scale, while in the
MVS scale, blood in stool is not a factor and fever is double
weighted only when temperature is above 38.4 °C. The differ-
ences regarding symptoms and disease provided no convin-
cing evidence for a more severe course for one pathogen
over the other. Patients with EIEC infections in our study
were more likely to visit their GP. However, this is probably
an artefact being a consequence of the healthcare system in
the Netherlands, where only physicians can request labora-
tory confirmation, thus all patients diagnosed with an EIEC
infection had visited their GP by definition. In contrast, PHS
can also request laboratory confirmation of patients with
shigellosis for cases that are identified during contact tracing
[20]. This explains why not every patient with Shigella spp.
visited their GP while patients diagnosed with EIEC did.
Furthermore, similar percentages of patients infected with
Shigella spp. and EIEC reported hospitalization, but patients
infected with Shigella spp. were more likely to be admitted
for longer periods. This may indicate a more severe disease
course.
In our study, no biological evidence was found to
support the current difference in approach for infec-
tions with Shigella spp. and EIEC, indicating that the
disease control measures for EIEC should be the same
as for Shigella spp. for several reasons. First, a reliable
Table 2 Symptoms and severity of infections with EIEC and Shigella, and culture-positive and culture-negative shigellosis





















Blood in stool (% present) 16 39 0.005 0.051 39 38 0.901 0.679
Mucus in stool (% present) 47 58 0.222 0.290 58 54 0.508 0.688
Abdominal pain (% present) 59 74 0.082 0.108 75 71 0.330 0.945
Abdominal cramps (% present) 72 82 0.194 0.115 82 83 0.662 0.310
Nausea (% present) 56 44 0.209 0.568 45 54 0.066 0.041
Headache (% present) 22 33 0.187 0.052 32 40 0.108 0.086
Fever (% present) 47 60 0.164 0.248 59 56 0.582 0.420
When fever, duration in days
(median (IQR))
3 (2.5–4.5) 2 (1–4) 0.334 0.165 2 (1–4) 2 (1–4) 0.802 0.698
When fever, maximum temperature
(mean ± sd)
40.0 ± 0.7 39.4 ± 0.9 0.063 0.413 39.4 ± 0.9 39.2 ± 0.8 0.084 0.179
Diarrhea (% present) 97 97 0.907 0.776 98 99 0.349 0.303
When diarrhea, duration in days
(median (IQR))
14 (7–19.5) 10 (6–14) <0.001 <0.001 9.5 (6–14) 14 (8–24) <0.001 0.001
When diarrhea, frequency in 24H
(median (IQR))
8 (6–14) 9 (6–15) 0.855 0.796 10 (6–15) 10 (6–16) 0.486 0.185
Vomiting (% present) 28 28 0.979 0.809 29 37 0.073 0.026
When vomiting, duration in days
(median (IQR))
2 (1–3) 1 (1–3) 0.508 0.929 1 (1–3) 2 (1–3) 0.033 0.167
When vomiting, frequency in 24H
(median (IQR))
3 (2–8) 2 (1–4) 0.166 0.001 2 (1–4) 3 (1–5.8) 0.525 0.027
Total number of symptoms
(median (IQR))
4 (3.0–5.3) 5 (4–6) 0.006 0.006 5 (4–6) 5 (4–6) 0.519 0.104
Severity scores:
- de Wit et al. (mean ± sd) 6.4 ± 2.6 7.5 ± 2.7 0.033 0.045 7.5 ± 2.7 7.7 ± 2.7 0.380 0.132
- Modified vesikari (mean ± sd) 7.4 ± 3.3 7.3 ± 2.8 0.852 0.943 7.3 ± 2.8 7.9 ± 2.8 0.028 0.007
Sd Standard deviation, IQR Interquartile range. aone S. flexneri and one EIEC isolate were excluded from analysis, because they caused a double-infection. Bold
values indicate significant results with p-values <0.05.
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separation of these bacteria by MMLs is technically
challenging and probably unachievable, as it is increas-
ingly realized that they should be classified as one
species as proposed by multiple research groups [8, 40].
Second, this study also associates EIEC infections with
serious infections although minor differences in
symptoms were observed compared to shigellosis. The
pathogenic behavior of EIEC is also reflected in its
involvement in multiple food-related outbreaks [26–30].
Although in some literature it is stated that S. sonnei
causes milder forms of shigellosis than the other species
of Shigella [41], in our study, as well as in other studies,
no differences were found in disease severity when
comparing S. sonnei and S. flexneri infections [42].
The limited sensitivity of culture from fecal samples
should be further investigated. Causes for this phenomenon
could be a low bacterial load, time between onset of symp-
toms and submission of the sample, and time between
submission of the sample and diagnostic procedures. Never-
theless, the proportion of infections from which bacteria
could be cultured in our study is comparable to other stud-
ies and is representative of the situation in the Netherlands
and other areas [23, 43] (de Boer et al., manuscript in
preparation).
Similar to others, we found that culture-negative cases
were less likely to report MSM contact, more likely to
report traveling and have a longer symptomatic period
[31, 33]. Others explained that their culture negative
cases reported higher travel rates because they are more
likely to be infected by EIEC [33]. However, this explan-
ation is not applicable to our study, as there is high
certainty that EIEC infections were not included in our
culture-negative group, because they were molecularly
typed as S. flexneri or S. sonnei with a specificity of at
least 98%. We suggest that laboratory confirmation
might have been requested later in the course of the dis-
ease for travelers, reducing the chance of obtaining an
isolate [23]. This is supported by the observation that
the time between onset of disease and sample collection
was longer for culture-negative cases in the earlier












PCR + a, b
(n = 244)








Bedrest (% present) 88 81 0.357 0.186 82 79 0.528 0.514
Leave of absence (% present) 56 53 0.709 0.703 53 47 0.220 0.737
When absence patient, duration
in days (median (IQR))
5 (3.0–7.8) 4 (3–7) 0.882 0.401 4 (3–7) 7 (3–10) 0.038 0.005
When absence caretaker, duration
in days (median (IQR))
0 (0–0) 0 (0–0) 0.554 0.185 0 (0–0) 0 (0–0) 0.389 0.171
Use of care facilities
GP (% visited) 100 91 0.015 0.037 91 93 0.299 0.851
When GP visited, number
of visits (median (IQR))
1.5 (1–2) 1 (1–2) 0.623 0.399 1 (1–2) 1 (1–2) 0.595 0.909
GP outside office hours (% visited) 9 9 0.989 0.537 9 10 0.694 0.757
Specialists (% visited) 16 13 0.732 0.830 13 16 0.388 0.965
When specialist visited, number
of visits (median (IQR))
1 (1–2) 1 (1–1) 0.797 0.799 1 (1–1) 1 (1–2) 0.122 0.553
Emergency room (% visited) 9 10 0.933 0.781 10 5 0.072 0.074
Hospitalization (% hospitalized) 3 9 0.180 0.270 9 5 0.163 0.443
When hospitalized, duration
in days (median (IQR))
1.5 (0.8–2.3) 3 (2–4) 0.179 0.027 3 (1.5–3.5) 3.5 (1–4.8) 0.244 0.648
IQR Interquartile range. aone S. flexneri and one EIEC isolate were excluded from analysis, because they caused a double-infection. Bold values indicate significant
results with p-values <0.05
Table 4 Degree secondary infections of infections with EIEC and Shigella, and culture-positive and culture-negative shigellosis






















Related patients (% present) 47 39 0.393 0.785 40 39 0.865 0.930
When related patients, total
number (median (IQR))
1 (1–2) 1 (1–2) 0.239 0.354 1 (1–2) 1 (1–3) 0.326 0.977
IQR Interquartile range. aone S. flexneri and one EIEC isolate were excluded from analysis, because they caused a double-infection. Bold values indicate significant
results with p-values <0.05
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studies [31, 33]. Unfortunately, in our study, data about
time of onset of disease was not available. In our study
the total number of symptoms in culture-positive and
culture-negative cases was comparable, in contrast to a
previous study in which culture-negative cases were
associated with a less severe course of disease [33] .
However, culture-negative cases were more likely to suf-
fer from nausea and vomiting and were symptomatic for
longer than culture-positive cases. Moreover, culture-
negative cases were associated with a longer absence
from work, probably a consequence of their longer
symptomatic period. Culture negative cases also had a
higher score on the MVS scale, while the scores of de
Wit scale were comparable. This discrepancy in the
scales was probably caused by extended periods of diar-
rhea and higher frequency of vomiting in culture-
negative cases; these factors are scored in the MVS scale
but not in the de Wit scale. The results of the two sever-
ity scales are discordant throughout this study, indicat-
ing that interpretation of research into enteric infections
depends highly on the severity scale chosen.
The current case definition for shigellosis was formu-
lated when molecular methods were not implemented
in routine diagnostics. Since their implementation, mo-
lecular methods have improved diagnostic capabilities,
especially for organisms that are challenging to culture
such as Shigella spp. and EIEC. However, because evi-
dence about the meaning of PCR positive results was
lacking, these methods are not yet incorporated into
the case definition of shigellosis. Our study demon-
strates that molecularly detected cases of shigellosis are
comparable to culture confirmed shigellosis cases.
There is no biological basis supporting the current case
definition of shigellosis in which only culture confirmed
cases are notifiable. Additionally, case control studies
have demonstrated that the molecular detection of the
ipaH gene in fecal samples was associated with cases
rather than controls, and others showed that the
sequence composition and quantity of Shigella spp. in
culture-negative cases was comparable to culture-
positive shigellosis cases [30, 38, 43–45]. Finally, guide-
lines from the European Union (EU), United States of
America (USA) and Australia recently amended case
definitions for shigellosis, and define molecular de-
tected infections as probable cases, which in Australia
should be notified, while in the EU and the USA
individual countries or states should define their own
notification criteria [19, 21, 22].
One of the strengths of this study is the inclusion of
samples and patient data representative for the whole of
the Netherlands, as a result of the collaboration with
MMLs and PHS. A second strength is that the clinical
outcomes and impact on public health of infections with
EIEC were investigated; these have not often been
described before [30]. A third strength is that the value
of molecular detection of Shigella spp. versus culture
was investigated in detail.
Limitations of this study are that the representation
of species is based on the Dutch situation and there-
fore no S. dysenteriae isolates, and only a few S. boy-
dii isolates were included in the comparison of
outcomes of Shigella spp. and EIEC. Second, not all
notified shigellosis cases were included, because not
all laboratories in the Netherlands participated in the
study, although participating laboratories had a rea-
sonable national geographic distribution. Third, the
study design introduces a bias towards more severe
infections and certain demographics such as age and
frailty, because only infections for which laboratory
confirmation was requested were included. Fourth, no
data was collected on date of onset of symptoms im-
peding correction for the comparison of symptomatic
periods. Fifth, the number of self-reported related pa-
tients was used to estimate secondary infection rate.
Although patients were asked to mention if they were
aware of any other people that fell ill before or after
them, common sources cannot be excluded with
certainty using this method. Last, the clinical and
epidemiological circumstances were not a result of
objective measurements, but were dependent on the
judgement and memory of the patients.
Conclusions
This study provides evidence to reconsider incorporating
molecular detection methods as well as infections with
EIEC in the case definition and guidelines for disease con-
trol measures regarding shigellosis. As our study showed
differences in risk factors between Shigella spp. infections
and EIEC infections and between culture-positive and
culture-negative shigellosis cases, the application of
different prevention strategies deserves attention.
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